Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Red ginseng powder, specifically the formulation TJ-3020, is a botanical product derived from the steamed and dried roots of *Panax ginseng* C.A. Meyer. It is traditionally used in East Asian medicine for its adaptogenic properties, which are primarily attributed to its concentration of ginsenosides. In clinical research, TJ-3020 has been investigated as a supportive care intervention to mitigate chemotherapy-induced fatigue and malaise in patients with advanced cancers, such as unresectable or recurrent pancreatic cancer. A Phase II randomized study (jRCTs041190040) conducted in Japan evaluated the efficacy of TJ-3020 in patients receiving nab-paclitaxel plus gemcitabine, though the study found that the treatment did not significantly improve chemotherapy-induced fatigue or malaise compared to the control group.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on red ginseng powder.